Study M213
Study name | Renshaw PF 1997 |
Title | Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study |
Overall design | The aim of this study was to investigate proton magnetic resonance spectra of the basal ganglia in medication-free outpatients with major depression (depression group, n = 41), prior to starting an 8-week standardized trial of open-label fluoxetine 20 mg/day, and matched comparison subjects (control group, n = 22). Upon completing the trial, subjects were classified as treatment responders (responder group, n = 18) if they had a post-trial HDRS score showing at least a 50% decrease from their initial score and this post-trial score was less than 7. Depressed subjects without this improvement on the HDRS were considered nonresponders (nonresponder group, n = 23). The 1H-MR resonances for N-acetyl aspartate, creatine and phosphocreatine, and choline-containing compounds. Metabolite quantification was reported relative to total creatine as the reference peak. |
Study Type | Type1; Type2; Type4; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-III-R diagnosed MDD, HAMD-17 >= 16 |
Sample size | 63 |
Tissue | Central; Brain; Basal ganglia; |
Platform | MRS; MRS: Signa 1.5 T scanner (General Electric Medical Systems, Milwaukee, WI); |
PMID | |
DOI | |
Citation | Renshaw PF, Lafer B, Babb SM, et al. Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 1997;41(8):837-43. |
Metabolite | Choline-containing compounds/(Creatine and Phosphocreatine) ratio; |
